Results 101 to 110 of about 2,463,634 (361)

Communicative Participation in Dysarthria: Perspectives for Management

Brain Sciences, 2022
Communicative participation is restricted in many conditions associated with dysarthria. This position paper defines and describes the construct of communicative participation. In it, the emergence of this construct is reviewed, along with the predictors
Allyson D. Page, Kathryn M. Yorkston
doaj   +1 more source

Patient reported outcome measures in rare diseases: a narrative review

Orphanet Journal of Rare Diseases, 2018
BackgroundRare diseases can lead to a significant reduction in quality of life for patients and their families. Ensuring the patients voice is central to clinical decision making is key to delivering, evaluating and understanding the efficacy of ...
A. Slade, Fatima Isa, Derek G Kyte, T. Pankhurst, L. Kerecuk, J. Ferguson, G. Lipkin, M. Calvert   +7 more
semanticscholar   +1 more source

Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies

Molecular Oncology, EarlyView.
Pre‐analytical variables strongly influence the analysis of extracellular RNA (cell‐free RNA; exRNA) derived from blood plasma. Their reporting is essential to allow interpretation and replication of results. By evaluating 200 exRNA studies, we pinpoint a lack of reporting pre‐analytical variables associated with blood collection, plasma preparation ...
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock   +16 more
wiley   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Patient-Reported Outcome Measures (PROMS) in Lymphoma

Current Oncology
Patient-reported outcome measures (PROMs) are often used to evaluate the impact of treatment and clinical decisions on the patient experience for patients with lymphoma.
Neha Akkad, Christopher R. Flowers
doaj   +1 more source

Simple Sensitivity Analysis for Differential Measurement Error [PDF]

arXiv, 2018
Simple sensitivity analysis results are given for differential measurement error of either the exposure or the outcome. In the case of differential measurement error of the outcome it is shown that the true effect of the exposure on the outcome on the risk ratio scale must be at least as large as the observed association between the exposure and the ...
arxiv  

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

The importance of qualitative methods for generating patient reported outcome measures and patient reported experience measures for pre-hospital and emergency care of stroke and heart attack [PDF]

, 2012
Context: The Patient Reported Outcomes for Vascular Emergencies: Interview Study (IS-PROVE) of patients and practitioners was conducted in a large regional ambulance service in the East Midlands region of the UK from 2010-2011.
Davy, Zowie, Siriwardena, A. Niroshan, Togher, Fiona   +2 more
core  

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Patient empowerment: The need to consider it as a measurable patient-reported outcome for chronic conditions

BMC Health Services Research, 2012
Background Health policy in the UK and elsewhere is prioritising patient empowerment and patient evaluations of healthcare. Patient reported outcome measures now take centre-stage in implementing strategies to increase patient empowerment.
McAllister Marion, Dunn Graham, Payne Katherine, Davies Linda, Todd Chris   +4 more
doaj   +1 more source